NCT00122447 - Cardiovascular Disease (CVD) Risk and Prevention in Early Glucose Intolerance | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 31, 2005

Primary Completion Date

May 31, 2011

Study Completion Date

May 31, 2011

Conditions

Impaired Glucose TolerancePrediabetic State

Interventions

DRUG

Aspirin

325 mg PO QD

DRUG

Alpha lipoic acid

600 mg PO BID

DRUG

Olmesartan

40 mg PO QD

DRUG

Placebo

"Identical placebo for each active comparator:~placebo aspirin 325 mg PO QD; placebo for alpha lipoic acid 600 mg PO BID; placebo for olmesartan 40 mg PO QD"

Trial Locations (2)

30303

Grady Health System, Atlanta

30322

Emory University Hospital, Atlanta